If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  Allegra-D Available In Time For Allergy Season KANSAS CITY, MO -- March 12, 1998 -- New relief for seasonal allergy sufferers with nasal congestion is being made available just in time for allergy season. Hoechst Marion Roussel’s Allegra-D(TM) (fexofenadine hydrochloride 60 mg and pseudoephedrine hydrochloride 120 mg) Extended-Release Tablets, a non-sedating antihistamine with decongestant, is now obtainable by prescription in the United States. Allegra-D offers safe, effective relief of seasonal allergy symptoms plus nasal congestion. Its continual effectiveness throughout the dosing period, coupled with the fact that the same dosage can be used for most patients aged 12 and over, makes Allegra-D a treatment option for seasonal allergy sufferers with nasal congestion. "Allergy sufferers have more treatment options available than ever before," said Michael Kaliner, M.D., medical director of the Institute for Asthma and Allergy, and section chief, allergy and immunology, Washington Hospital Center, in Washington, MD. "Allegra-D offers the same beneficial therapeutic effects of Allegra combined with a decongestant." Allegra-D was cleared for marketing by the U.S. Food and Drug Administration for relief of seasonal allergic rhinitis in December 1997. The labelling of Allegra-D Extended-Release Tablets recommends dosing of one tablet twice daily. The recommended starting dose for patients with decreased kidney function is one tablet daily. Allegra-D is a good choice for patients with nasal symptoms and congestion who also have ocular allergy symptoms or patients reluctant to use nasal sprays. Due to pseudoephedrine, Allegra-D is contraindicated in patients with narrow-angle glaucoma or urinary retention, in patients receiving monamine oxidase inhibitor therapy and in patients with severe hypertension or severe coronary artery disease. Allegra-D should also be used with caution in patients with hypertension, diabetes mellitus, ischemic heart disease, increased intraocular pressure, hyperthyroidism, renal impairment, or prostatic hypertrophy. The most commonly reported adverse events for Allegra-D compared with pseudoephedrine HCl were headache (13.0 percent vs. 17.4 percent), insomnia (12.6 percent vs. 13.3 percent), and nausea (7.4 percent vs. 5.0 percent). The most commonly reported adverse events for Allegra compared with placebo were viral infection (cold, flu) (2.5 percent vs. 1.5 percent), nausea (1.6 percent vs. 1.5 percent) and dysmenorrhea (1.5 percent vs. 0.3 percent). Seasonal allergic rhinitis is a chronic condition occurring predominantly during the spring and fall allergy seasons that is caused by the body's reaction to allergens that enter through the respiratory tract. According to the National Institute of Allergy and Infectious Diseases (NIAID), allergies affect as many as 50 million people. Typical allergens that cause SAR are grass and tree pollens, moulds and ragweed pollen. Symptoms typically affect the nose, but patients also report itchy, watery eyes and nasal congestion. Seasonal allergic rhinitis often remains undiagnosed and untreated because people mistake their symptoms as related to a cold or the flu. More information on: Hoechst Marion Roussel and, More information on: Allegra
|
